There are limited data on the overall benefit of endocrine therapies for patients with low level (1–10%) ER expression but they currently suggest possible benefit, so patients are considered eligible for endocrine treatment.” There are data that suggest invasive cancers with these results are heterogeneous in both behavior and biology and often have gene expression profiles more similar to ER negative cancers. This evidence concerns the gene ESR1 and cancer.